Abstract

Background:
Central serous chorioretinopathy (CSCR) has been associated with multiple risk factors, and increasing evidence suggested a possible link between phosphodiesterase-5 (PDE5) inhibitors and the development of CSCR. Hence, awareness is important for timely diagnosis and management.
Case Presentation:
A 47-year-old male with a history of well-controlled diabetes mellitus, dyslipidemia, and Parkinson’s disease presented with a 3-day history of blurred vision in the left eye following a single 20 mg dose of tadalafil. Ophthalmic examination revealed reduced visual acuity in the affected eye. Optical coherence tomography demonstrated subretinal fluid with a small pigment epithelial detachment, supporting the diagnosis of central serous chorioretinopathy. The diagnosis was made based on the clinical presentation, recent PDE5 inhibitor use, and imaging findings. The patient was advised to discontinue tadalafil, and close follow-up was arranged. Subsequent evaluation demonstrated improvement in visual symptoms, with signs of subretinal fluid resolution on follow-up imaging, supporting the presumed association between tadalafil use and CSCR.
Conclusion:
This case emphasized on the importance of considering recent PDE5 inhibitor use in patients presenting with acute visual symptoms. Discontinuation of the suspected agent might lead to clinical improvement, and early recognition with prompt intervention might help prevent potential long-term visual complications in drug-associated CSCR.

Key words: Case report, central serous chorioretinopathy, CSCR, tadalafil, case report